SCHEMBL19137965

SCHEMBL19137965

CN1CCN(c2ccc(-c3nc4cc(Cl)c(Cl)cc4[nH]3)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 1/20 0.63
▸ SOAT1 P35610 1/20 0.63
▸ KCNH2 Q12809 1/20 0.63
▸ ALDH1A1 P00352 4/20 0.62
▸ SMN1; SMN2 Q16637 4/20 0.62
▸ TOP1 P11387 3/20 0.62
▸ TOP2A P11388 3/20 0.62
▸ HPGD P15428 1/20 0.62
▸ HSD17B10 Q99714 1/20 0.62
▸ MEN1 O00255 2/20 0.56
▸ MAPT P10636 2/20 0.56
▸ BLM P54132 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ SLCO2B1 O94956 1/20 0.56
▸ GLA P06280 1/20 0.56
▸ RECQL P46063 1/20 0.56
▸ BCL2L1 Q07817 1/20 0.56
▸ SLCO1B3 Q9NPD5 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ SLCO1B1 Q9Y6L6 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19175932 0.91 DGAT1 (0.59) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL19137939 0.90 DGAT1 (0.61) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL19137938 0.88 NPBWR1 (0.59) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL19137962 0.87 DGAT1 (0.67) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL19137947 0.87 CCR2 (0.58) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL23709610 0.86 ALDH1A1 (0.61) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL19137934 0.86 ACHE (0.69) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL19137933 0.86 RHEB (0.58) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL21017604 0.85 DGAT1 (0.63) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2
SCHEMBL24075398 0.85 DGAT1 (0.66) DGAT1SOAT1KCNH2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 — — US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 — — US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 — — US disclosed
WO-2018191146-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-10-18 — — WO disclosed
US-20170210741-A1 Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof SOUTHERN RESEARCH INSTITUTE 2017-07-27 — — US disclosed
US-20170210741-A1 Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof SOUTHERN RESEARCH INSTITUTE 2017-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS DGAT1 3962/4885SOAT1 3072/4885KCNH2 4734/4885
US-20170210741-A1 Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof WNT1, WNT3, CTNNB1 DGAT1 2252/4885SOAT1 2222/4885KCNH2 4391/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS DGAT1 2656/4885SOAT1 1694/4885KCNH2 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback